# A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

> **NCT06713135** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Santhera Pharmaceuticals** · enrollment: 80 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** vamorolone 40 mg/mL oral suspension

## Key facts

- **NCT ID:** NCT06713135
- **Lead sponsor:** Santhera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-10
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06713135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06713135, "A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06713135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*